Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Purpose: Herein we report the clinical and dosimetric experience for patients with metastases treated with palliative simulation-free radiation therapy (SFRT) at a single institution.

Methods And Materials: SFRT was performed at a single institution. Multiple fractionation regimens were used. Diagnostic imaging was used for treatment planning. Patient characteristics as well as planning and treatment time points were collected. A matched cohort of patients with conventional computed tomography simulation radiation therapy (CTRT) was acquired to evaluate for differences in planning and treatment time. SFRT dosimetry was evaluated to determine the fidelity of SFRT. Descriptive statistics were calculated on all variables and statistical significance was evaluated using the Wilcoxon signed rank test and test methods.

Results: Thirty sessions of SFRT were performed and matched with 30 sessions of CTRT. Seventy percent of SFRT and 63% of CTRT treatments were single fraction. The median time to plan generation was 0.88 days (0.19-1.47) for SFRT and 1.90 days (0.39-5.23) for CTRT ( = .02). The total treatment time was 41 minutes (28-64) for SFRT and 30 minutes (21-45) for CTRT ( = .02). In the SFRT courses, the maximum and mean deviations in the actual delivered dose from the approved plans for the maximum dose were 4.1% and 0.07%, respectively. All deliveries were within a 5% threshold and deemed clinically acceptable.

Conclusions: Palliative SFRT is an emerging technique that allowed for a statistically significant lower time to plan generation and was dosimetrically acceptable. This benefit must be weighed against increased total treatment time for patients receiving SFRT compared with CTRT, and appropriate patient selection is critical.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9594122PMC
http://dx.doi.org/10.1016/j.adro.2022.101091DOI Listing

Publication Analysis

Top Keywords

radiation therapy
16
treatment time
16
plan generation
12
sfrt
11
simulation-free radiation
8
treatment planning
8
patients receiving
8
sfrt performed
8
planning treatment
8
time plan
8

Similar Publications

Objectives: Empty sella is the herniation of the subarachnoid space into the sella turcica; either secondary to identifiable causes (e.g., surgery or radiotherapy); or spontaneously, which is termed primary empty sella (PES).

View Article and Find Full Text PDF

Objective: Thymic tumors are a rare group of anterior mediastinal tumors. Surgery is the primary treatment. Adjuvant treatment is used in select cases.

View Article and Find Full Text PDF

BACKGROUND Non-traumatic bladder rupture, a rare yet potentially life-threatening condition, can stem from diverse factors such as malignancies, bladder inflammation, or bladder diverticulum rupture. Pelvic radiotherapy, in extremely rare instances, can lead to radiation cystitis and subsequent bladder fistula formation. Patients with such conditions often present with abdominal pain, hematuria, oliguria, and urinary ascites.

View Article and Find Full Text PDF

Introduction: Trastuzumab deruxtecan (T-DXd) has revolutionised treatment for metastatic breast cancer (MBC). While effective, its high cost and toxicities, such as fatigue and nausea, pose challenges.

Method: Medical records from the Joint Breast Cancer Registry in Singapore were used to study MBC patients treated with T-DXd (February 2021-June 2024).

View Article and Find Full Text PDF

Background: Breast cancer treatment, particularly during the perioperative period, is often accompanied by significant psychological distress, including anxiety and uncertainty. Mobile health (mHealth) interventions have emerged as promising tools to provide timely psychosocial support through convenient, flexible, and personalized platforms. While research has explored the use of mHealth in breast cancer prevention, care management, and survivorship, few studies have examined patients' experiences with mobile interventions during the perioperative phase of breast cancer treatment.

View Article and Find Full Text PDF